Cargando…
Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment
Background and Objectives: Brolucizumab (IVBr) is a recently introduced anti-vascular endothelial growth factor (anti-VEGF) which has been found to be very effective in treating neovascular age-related macular degeneration (nAMD). We reported our findings in a case of nAMD that developed intraocular...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608434/ https://www.ncbi.nlm.nih.gov/pubmed/37893574 http://dx.doi.org/10.3390/medicina59101856 |
_version_ | 1785127779499507712 |
---|---|
author | Ueji, Natsuki Mase, Yoko Kubo, Akiko Matsubara, Hisashi Chujo, Shinichiro Matsui, Yoshitsugu Kondo, Mineo |
author_facet | Ueji, Natsuki Mase, Yoko Kubo, Akiko Matsubara, Hisashi Chujo, Shinichiro Matsui, Yoshitsugu Kondo, Mineo |
author_sort | Ueji, Natsuki |
collection | PubMed |
description | Background and Objectives: Brolucizumab (IVBr) is a recently introduced anti-vascular endothelial growth factor (anti-VEGF) which has been found to be very effective in treating neovascular age-related macular degeneration (nAMD). We reported our findings in a case of nAMD that developed intraocular inflammation (IOI) after IVBr injections. Materials and Methods: A 79-year-old man was referred to our hospital complaining of reduced vision in both eyes of one-month’s duration. His decimal best-corrected visual acuity (BCVA) was 0.9 in the right eye and 1.0 in the left eye. He was diagnosed with nAMD in the left eye and was treated with intravitreal aflibercept (IVA). Despite the three-monthly IVA injections, the serous retinal pigment epithelial detachment (PED) and subretinal fluid (SRF) remained, and the VA gradually decreased to 0.1. Because of the patient being refractory to aflibercept treatment, we switched to 3-monthly IVBr injections. The BCVA gradually improved to 0.3 and optical coherence tomography (OCT) showed an absence of the serous PED and SRF. Three weeks after his third IVBr, he returned to our hospital with a complaint of reduced vision in his left eye that he first noted two weeks earlier. Our examination of the left eye showed signs of IOI mainly in the anterior chamber. The inflammation improved with topical steroids but the treatment of the IOI was delayed for two weeks. The patient was instructed that it was important to begin the treatment as soon as the symptoms of IOI developed. We then performed the Mini-Mental State Examination (MMSE), and his score indicated that he had cognitive impairment. Conclusions: We concluded that before beginning IVBr treatment in nAMD patients, a careful assessment must be made of the cognitive status of the patient. |
format | Online Article Text |
id | pubmed-10608434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106084342023-10-28 Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment Ueji, Natsuki Mase, Yoko Kubo, Akiko Matsubara, Hisashi Chujo, Shinichiro Matsui, Yoshitsugu Kondo, Mineo Medicina (Kaunas) Case Report Background and Objectives: Brolucizumab (IVBr) is a recently introduced anti-vascular endothelial growth factor (anti-VEGF) which has been found to be very effective in treating neovascular age-related macular degeneration (nAMD). We reported our findings in a case of nAMD that developed intraocular inflammation (IOI) after IVBr injections. Materials and Methods: A 79-year-old man was referred to our hospital complaining of reduced vision in both eyes of one-month’s duration. His decimal best-corrected visual acuity (BCVA) was 0.9 in the right eye and 1.0 in the left eye. He was diagnosed with nAMD in the left eye and was treated with intravitreal aflibercept (IVA). Despite the three-monthly IVA injections, the serous retinal pigment epithelial detachment (PED) and subretinal fluid (SRF) remained, and the VA gradually decreased to 0.1. Because of the patient being refractory to aflibercept treatment, we switched to 3-monthly IVBr injections. The BCVA gradually improved to 0.3 and optical coherence tomography (OCT) showed an absence of the serous PED and SRF. Three weeks after his third IVBr, he returned to our hospital with a complaint of reduced vision in his left eye that he first noted two weeks earlier. Our examination of the left eye showed signs of IOI mainly in the anterior chamber. The inflammation improved with topical steroids but the treatment of the IOI was delayed for two weeks. The patient was instructed that it was important to begin the treatment as soon as the symptoms of IOI developed. We then performed the Mini-Mental State Examination (MMSE), and his score indicated that he had cognitive impairment. Conclusions: We concluded that before beginning IVBr treatment in nAMD patients, a careful assessment must be made of the cognitive status of the patient. MDPI 2023-10-19 /pmc/articles/PMC10608434/ /pubmed/37893574 http://dx.doi.org/10.3390/medicina59101856 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Ueji, Natsuki Mase, Yoko Kubo, Akiko Matsubara, Hisashi Chujo, Shinichiro Matsui, Yoshitsugu Kondo, Mineo Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment |
title | Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment |
title_full | Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment |
title_fullStr | Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment |
title_full_unstemmed | Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment |
title_short | Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment |
title_sort | intraocular inflammation secondary to intravitreal brolucizumab injection for neovascular age-related macular degeneration in a patient with cognitive impairment |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608434/ https://www.ncbi.nlm.nih.gov/pubmed/37893574 http://dx.doi.org/10.3390/medicina59101856 |
work_keys_str_mv | AT uejinatsuki intraocularinflammationsecondarytointravitrealbrolucizumabinjectionforneovascularagerelatedmaculardegenerationinapatientwithcognitiveimpairment AT maseyoko intraocularinflammationsecondarytointravitrealbrolucizumabinjectionforneovascularagerelatedmaculardegenerationinapatientwithcognitiveimpairment AT kuboakiko intraocularinflammationsecondarytointravitrealbrolucizumabinjectionforneovascularagerelatedmaculardegenerationinapatientwithcognitiveimpairment AT matsubarahisashi intraocularinflammationsecondarytointravitrealbrolucizumabinjectionforneovascularagerelatedmaculardegenerationinapatientwithcognitiveimpairment AT chujoshinichiro intraocularinflammationsecondarytointravitrealbrolucizumabinjectionforneovascularagerelatedmaculardegenerationinapatientwithcognitiveimpairment AT matsuiyoshitsugu intraocularinflammationsecondarytointravitrealbrolucizumabinjectionforneovascularagerelatedmaculardegenerationinapatientwithcognitiveimpairment AT kondomineo intraocularinflammationsecondarytointravitrealbrolucizumabinjectionforneovascularagerelatedmaculardegenerationinapatientwithcognitiveimpairment |